Through its signaling effects, it helps the body adapt to physical stress, injury, and repetitive strain while supporting communication between the gut, nervous system, and musculoskeletal tissues
Certain side effects have been reported in clinical trials, including gastrointestinal discomfort and allergic reactions
The compound may work synergistically with NAD+ precursors like NMN or NR, potentially enhancing metabolic benefits
High doses, repeated administration, vulnerable populations (pregnant animals), and sensitive tissues (gastrointestinal tract, reproductive organs) have all been evaluated
Tirzepatide Tirzepatide sold as Mounjaro for diabetes and Zepbound for obesity is a dual agonist at both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors